Potential drugs and methods for preventing or delaying the progression of huntington's disease

Recent Patents on CNS Drug Discovery

Volumn 6, Issue 2, 2011, Pages 80-90

  Sari, Youssef ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Huntington's disease; Neurodegenerative diseases; Neuroprotection; Oxidative stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; COLIVELIN; DIMEBON; EFAROXAN; FIBROBLAST GROWTH FACTOR 2; GELDANAMYCIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GUANIDINE DERIVATIVE; HUNTINGTIN; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS;

EID: 79959333019     PISSN: 15748898     EISSN: 15748898     Source Type: Journal    
DOI: 10.2174/157488911795933884     Document Type: Article

References (151)

1. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315 (20): 1267-76.
2. Ross CA. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002; 35 (5): 819-22.
3. (HDCRG), H. s. D. C. R. G., A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72(6): 971-83.
4. McMurray CT. Huntington's disease: New hope for therapeutics. Trends Neurosci 2001; 24 (11 Suppl): S32-8.
5. Myers RH, Marans KS, MacDonald ME. Huntington's disease. In: genetic instabilities and hereditary neurological diseases. (R.D. Wells & S.T. Warren, Eds) Academic Press, San Diego 1998; 301-23.
6. Brocklebank D, Gayan J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, et al. Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. Am J Med Genet B Neuropsychiatr Genet 2009; 150B (3): 425-9.
7. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3): 537-48.
8. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knockin mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 2003; 465(1): 11-26.
9. de la Monte SM, Vonsattel JP, Richardson EPJ. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988; 47(5): 516-25.
10. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EPJ. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44(6): 559-77.
11. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998, 57 (5), 369-84.
12. Peschanski M, Bachoud-Levi AC, Hantraye P. Integrating fetal neural transplants into a therapeutic strategy: The example of Huntington's disease. Brain 2004; 127: 1219-28.
13. Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000; 161(1): 194-202.
14. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002; 73 (6): 678-85.
15. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356(9246): 1975-9.
16. Freed, C.R., Kaddis, F.G. Method of treating Huntington's disease using HNT neurons. US6254865 (2001).
17. Hurlbert MS, Gianani RI, Hutt C, Freed CR, Kaddis FG. Neural transplantation of hNT neurons for Huntington's disease. Cell Transplant 1999; 8(1): 143-51.
18. Alberch J, Perez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res 2004; 146: 195-229.
19. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 1998; 27(1): 1-39.
20. Kruttgen A, Saxena S, Evangelopoulos ME, Weis J. Neurotrophins and neurodegenerative diseases: Receptors stuck in traffic? J Neuropathol Exp Neurol 2003; 62(4): 340-50.
21. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001; 63(1): 71-124.
22. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72(3): 1283-93.
23. Zusev M, Gozes I. Differential regulation of activity-dependent uroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004; 123(1-3): 33-41.
24. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activitydependent neuroprotective protein in astrocytes. Neuron Glia Biol 2004; 1(3): 193-9.
25. Sari Y. Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse. Neurosci 2009; 158(4): 1426-35.
26. Sari Y, Gozes I. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Brain Res Rev 2006; 52(1): 107-18.
27. Gozes I. Activity-dependent neuroprotective protein: From gene to drug candidate. Pharmacol Ther 2007; 114(2): 146-54.
28. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000; 866 (1-2): 257-61.
29. Spires TL, Grote HE, Varshney NK, Cordery PM van Dellen A, Blakemore C, Hannan AJ. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004; 24(9): 2270-6.
30. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Sci 2001; 293(5529): 493-8.
31. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martin-Ibanez R, Munoz MT, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 2004; 24(35): 7727-39.
32. Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, et al. Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther 2010, 335 (1), 13-22.
33. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118(1): 127-38.
34. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389(6653): 856-60.
35. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 2004; 24(17): 4250-8.
36. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-22.
37. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007; 27 (43): 11758-68.
38. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci 2007; 27(16): 4424-34.
39. Pineda JR, Canals JM, Bosch M, Adell A, Mengod G, Artigas F, et al. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem 2005; 93(5): 1057-68.
40. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95(1): 55-66.
41. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004; 9(5): 682-8.
42. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81(5-6): 294-330.
43. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 2005; 52(2): 133-9.
44. Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, et al. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 2004; 78 (6): 855-67.
45. Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 2007; 117(10): 2889-902.
46. Winkler J, Thal LJ, Gage FH, Fisher LJ. Cholinergic strategies for Alzheimer's disease. J Mol Med 1998; 76(8): 555-67.
47. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003; 10(2); 86-98.
48. Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer's disease: Are we focusing on the wrong molecule? J Neural Transm Suppl 2002; (62): 241-52.
49. Lane RM, Kivipelto M, Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 2004; 27(3): 141-9.
50. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H J, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348(14): 1333-41.
51. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336 (17): 1216-22.
52. Buccafusco, J.J., Terry, A.V., Beach, J., Jonnala, R.R. Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders. US6881738 (2005).
53. Tebano MT, Martire A, Chiodi V, Ferrante A, Popoli P. Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: A possible key mechanism in the pathophysiology of Huntington's disease. Scientific World J 2010; 10: 1768-82.
54. Lesort M, Lee M, Tucholski J, Johnson GV. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278(6); 3825-30.
55. Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, et al. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004; 91(2); 413-22.
56. Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006; 116 (5): 1410-24.
57. Simmons, D., Lynch, G., Kramar, E. Upregulating activity or expression of BDNF to mitigate cognitive impairment in asymptomatic Huntington's subjects. US20080176793 (2008).
58. Powrozek TA, Sari Y, Singh RP, Zhou FC. Neurotransmitters and substances of abuse: Effects on adult neurogenesis. Curr Neurovasc Res 2004; 1(3): 251-60.
59. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998, 44 (5), 324-35.
60. Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav 2002; 73 (2): 317-26.
61. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997; 17(8): 2785-95.
62. Vaidya VA, Terwilliger RM, Duman RS. Role of 5-HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 1999; 262(1): 1-4.
63. Haque NS, Isacson O. Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell Transplant 2000; 9(5): 623-7.
64. Bjugstad KB, Zawada WM, Goodman S, Free CR. IGF-1 and bFGF reduce glutaric acid and 3-hydroxyglutaric acid toxicity in striatal cultures. J Inherit Metab Dis 2001; 24(6): 631-47.
65. Palmer TD, Ray J, Gage FH. FGF-2-responsive neuronal progenitors reside in proliferative and quiescent regions of the adult rodent brain. Mol Cell Neurosci 1995; 6(5): 474-86.
66. Zhou D, DiFiglia M. Basic fibroblast growth factor enhances the growth of postnatal neostriatal GABAergic neurons in vitro. Exp Neurol 1993; 122(2): 171-88.
67. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2005; 102(50): 18189-94.
68. Ellerby, L., Greenberg, D., Anderson, J., Jin, K. Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in Huntington's disease. US20090111748 (2009).
69. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, et al. Glial cell line-derived neurotrophic factor reverses toxininduced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182(1): 107-11.
70. Kim BT, Rao VL, Sailor KA, Bowen KK, Dempsey RJ. Protective effects of glial cell line-derived neurotrophic factor on hippocampal neurons after traumatic brain injury in rats. J Neurosurg 2001; 95(4): 674-9.
71. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2006; 103 (24): 9345-50.
72. Perez-Navarro, E.; Arenas, E.; Reiriz, J.; Calvo, N.; Alberch, J., Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience 1996, 75 (2), 345-52.
73. Watabe K, Ohashi T, Sakamoto T, Kawazoe Y, Takeshima T, Oyanagi K, et al. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res 2000; 60(4): 511-9.
74. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Sci 1993; 260(5111): 1130-2.
75. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS, Rosenthal A. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 1994; 13(5): 1245-52.
76. Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 2005; 193(1): 65-74.
77. Martin, D., Miller, G. Method for treating Huntington's diease using glial cell line-derived neurotrophic factor GDNF protein product. US5741778 (1998).
78. Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 886(1-2): 82-98.
79. Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 2005; 58(2): 224-33.
80. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAVmediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20(12): 4686-700.
81. Kordower JH, Emborg ME, Bloch J, Ma, SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Sci 2000; 290(5492): 767-73.
82. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9(5): 589-95.
83. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell linederived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59(3): 459-66.
84. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ERJr, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurol 2003; 60(1): 69-73.
85. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 2005; 57(2): 298-302.
86. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102 (2): 216-22.
87. Acsadi G, Anguelov RA, Yang H, Toth G, Thomas R, Jani A, et al. Increased survival and function of SOD1 mice after glial cellderived neurotrophic factor gene therapy. Hum Gene Ther 2002; 13(9): 1047-59.
88. Lu YY, Wang LJ, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci Res 2003; 45(1): 33-40.
89. Wang LJ, Lu YY, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22(16): 6920-8.
90. Henderson CE, Yamamoto Y, Livet J, Arce V, Garces A, deLapeyriere O. Role of neurotrophic factors in motoneuron development. J Physiol Paris 1998; 92(3-4): 279-81.
91. Sendtner M, Pei G, Beck M, Schweizer U, Wiese S. Developmental motoneuron cell death and neurotrophic factors. Cell Tissue Res 2000; 301(1): 71-84.
92. Eketjall S, Fainzilber M, Murray-Rust J, Ibanez CF. Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J 1999; 18(21): 5901-10.
93. Colin E, Regulier E, Perrin V, Durr A, Brice A, Aebischer P, et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005; 21(6): 1478-88.
94. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2(6): 831-7.
95. Pardo R, Colin E, Regulier E, Aebischer P, Deglon N, Humbert S, et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci 2006; 26(5): 1635-45.
96. Rangone H, Poizat G, Troncoso J, Ross CA, MacDonald ME, Saudou F, et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci 2004; 19(2): 273-9.
97. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, et al. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 2005; 14(11): 1569-77.
98. Rangone H, Pardo R, Colin E, Girault JA, Saudou F, Humbert S. Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQhuntingtin- induced toxicity by rescuing proteasome impairment. J Biol Chem 2005; 280(23): 22021-8.
99. Wilczak N, de Keyser J. Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocr Dev 2005; 9:160-9.
100. Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 2006; 9 (11): 1371-81.
101. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001; 28(2): 131-8.
102. Devos D, Moreau C, Lassalle P, Perez T, De Seze J, Brunaud-Danel V, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurol 2004; 62 (11): 2127-9.
103. Chiba T, Yamada M, Sasabe J, Terashita K, Aiso S, Matsuoka M, et al. Colivelin prolongs survival of an ALS model mouse. Biochem Biophys Res Commun 2006; 343(3): 793-8.
104. Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I. Humanin and colivelin: Neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev 2006; 12(2): 113-22.
105. Sari Y, Chiba T, Yamada M, Rebec GV, Aiso S. A novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL/6 mice: signaling pathway investigations. Neurosci 2009; 164(4): 1653-64.
106. Sari, Y., Chiba, T., Aiso, S. Colivelin as a neuroprotective factor. US057413 (2009).
107. Chiba, T., Kita, Y., Matsuoka, M., Terashita, K., Aiso, S., Nishimoto, I., Nishimoto, T. Therapeutic agent for neurodegenerative diseases. US20080227699 (2008).
108. Chiba T, Yamada M, Hashimoto Y, Sato M, Sasabe J, Kita Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci 2005; 25(44): 10252-61.
109. Ying G, Iribarren P, Zhou Y, Gong W, Zhang N, Yu ZX, et al. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol 2004; 172(11): 7078-85.
110. Villegas, S., Kelner, G.S., Unett, D.J., Gatlin, J., Human G proteincoupled receptor and modulators thereof for the treatment of cell death-related disorders. US20080125491 (2008).
111. Hashimoto Y, Suzuki H, Aiso S, Niikura T, Nishimoto I, Matsuoka M. Involvement of tyrosine kinases and STAT3 in Humaninmediated neuroprotection. Life Sci 2005; 77(24): 3092-104.
112. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, et al. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 2003; 24(9): 1413-23.
113. Gozes, I., Miller, J. Use of ANDF polypeptides for treating peripheral neurotoxicity. US7452867 (2008).
114. Brenneman, D.E., Castellon, R., Spong, C.Y., Hauser, J.M., Gozes, I. Neurotrophic components of ADNF I complex. US7427590 (2008).
115. Brenneman, D.E. Neurotrophic peptides of activity dependent neurotrophic factor. US6174862 (2001).
116. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990; 13(7): 286-9.
117. Fonnum F, Storm-Mathisen J, Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neurosci 1981; 6(5): 863-73.
118. Harper PS. Huntington's Disease. W.b. Saunders: London. 1996, 2nd Edition.
119. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamateglutamine cycling: downstream effects of the Huntington mutation. Brain 2002; 125(Pt 8): 1908-22.
120. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001; 8(5): 807-21.
121. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neurosci 2008; 153(1): 329-37.
122. Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008; 33(2): 232-7.
123. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol 2001; 58(3): 365-70.
124. Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009; 34(1): 78-86.
125. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433 (7021): 73-7.
126. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurol 2006; 67(1): 20-7.
127. Weber, E., Keana, J.F.W. Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists. US6251948 (2001).
128. Reddy, J.R. Preventive and therapeutic vaccine for Huntington's disease. US20090175891 (2009).
129. Slusher, B.S., Wozniak, K. Naaladase inhibitors for treating huntington's disease. US20050080139 (2005).
130. Jackson PF, Slusher BS. Design of NAALADase inhibitors: A novel neuroprotective strategy. Curr Med Chem 2001; 8(8): 949-57.
131. Hung, D. Methods and compositions for treating Huntington's disease. US20070117834 (2007).
132. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010; 23(8): 518-23.
133. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 2008; 3: 15.
134. Ferrante, R.J., Method of using coenzyme Q10 to treat Huntington's disease. US7901675 (2011).
135. Von Borstel, R.W. Compositions and methods for treatment of mitochondrial diseases. US7915233 (2011).
136. Alanine, A., Buettelmann, B., Neidhart, M.-P.H., Jaeschke, G., Pinard, E., Wyler, R. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists. US6432985 (2002).
137. Griffin, J.H., Zlokovic, B.Y. Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC). US7074402 (2006).
138. Zhang, H.-C., Kuo, G.-H., Maryanoff, B.E., Ye, H., O'Neill, D., Shen, L., Demarest, K., Conway, B.R., McComsey, D.F. Substituted pyrroline kinase inhibitors. US7125878 (2006).
139. Ichiro, K., Wanzhao, L., Wang, Y.-L., Wada, K., Goto, J., Murata, M. Inhibition of the expression of Huntington gene. US7589189 (2009).
140. Sah, D.W.-Y., Hadwiger, P., Roehl, I., Bramlage, B., Tan, P., Vornlocher, H.P., Bumcrot, D. Compositions and mehtods for inhibiting expression of Huntingtin gene. US7749978 (2010).
141. Fischer, D.F., Janssen, R.A., De Pril, R., Van Steenhoven, D.M., Kwak, S., Howland, D.S., Signer, E. Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases. WO2009098196 (2009).
142. Kaemmerer, W.F. Treatment of neurodegenerative disease through intracranial delivery of siRNA. US7605249 (2009).
143. Kaemmerer, W.F., Kaytor, M.D. Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna. US7732591 (2010).
144. Kaemmerer, W.F., Kaytor, M.D. Isolated nucleic acid duplex for reducing Huntington gene expression. US7902352 (2011).
145. Kalchman, M., Hayden, M.R., Hackam, A., Chopra, V., Goldberg, P. Apoptosis modulators that interact with the Huntington's disease gene. US6235879 (2001).
146. Khoshnan, A., Ko, J., Patterson, P.H. Antibodies that bind to an epitope on the Huntington's disease protein. US20080107657 (2008).
147. Mercken, M., Benson, J.M. Anti-amyloid antibodies, compositions, methods and uses. US20050129695 (2005).
148. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, et al. Geldanamycin activates a heat shock response and inhibits Huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 2001; 10(12): 1307-15.
149. Hay DG, Sathasivam K., Tobaben S, Stahl B, Marber M, Mestril R, et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 2004; 13(13): 1389-405.
150. Diamond, M.I., Pollitt, S.K. Protein aggregation regulators. US7803559 (2010).
151. Whitehurst, T.K., Pianca, A.M. Treatment of Huntington's disease by brain stimulation. US20040225335 (2004).